Related Experiment Video
Updated: Jun 14, 2025
Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells
Published on: February 4, 2021
Analysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on
Alyssa M Pereslete1,2,3, Melissa E Hughes2,3, Alyssa R Martin2,3
1Herbert Wertheim College of Medicine, Florida International University, Miami, Florida, USA.
Background:
There are limited data regarding HER2-low expression dynamics between matched primary tumors and brain metastases (BrMs) in breast cancer. HER2-low expression has emerged as a new therapeutic biomarker for highly active antibody-drug conjugates with emerging intracranial activity.
Methods:
Patients with metastatic breast cancer and BrMs seen at an NCI-designated center between 2003 and 2023 were identified. HER2 expression was defined as HER2-positive (3+, 2+/ISH amplified), HER2-low (1+, 2+/ISH negative), or HER2-0 by ASCO-CAP guidelines. Estrogen receptor (ER) status was defined as ER ≥1%. Multivariate survival analyses by Cox proportional hazard models were determined from the time of BrM resection to death or last follow-up between the 3 subtypes, controlling for ER and age.
Results:
Among 197 matched primary and resected BrMs, 81% exhibited HER2 expression in the brain: 61% HER2-positive, 20% HER2-low, and 19% HER2-0. Concordance was high in HER2-positive primary tumors with 100% retaining HER2 expression (97% retained HER2-positive expression and 2.7% switched to HER2-low). HER2-0 primaries frequently showed HER2 gain in BrMs to HER2-low (35%) or HER2-positive (5.4%) status. Among 48 HER2-low primary tumors, 52% were discordant for HER2 status in the brain with 21% testing HER2-positive and 31% testing HER2-0. In adjusted analyses, patients with HER2-positive BrMs had significantly lower death risk than patients with HER2-low BrMs (HR = 0.41, P = .0006); no difference was observed between HER2-0 and HER2-low.
Conclusions:
In this retrospective analysis, HER2 expression is common in breast cancer BrMs, emphasizing the need for improved, noninvasive diagnostics. Patients with HER2-low and HER2-0 BrMs face inferior survival, presenting an unmet clinical need.
